Neurology Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-04-03　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 74 Bn
2033 年預估規模: USD 104 Bn
年複合成長率 CAGR: 4.98%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-04-03頁數 152報告編號 CMI9418

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Neurology Drugs Market, By Disease Type (Alzheimers Disease, Parkinsons Disease, Epilepsy, Multiple Sclerosis, Migraine, Huntingtons Disease, and Others), By Drug Class (Antiepileptics, Antipsychotics, Dopamine Agonists, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Analgesics (Migraine-specific), and Others), By Route of Administration (Oral, Injectable, and Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

報告摘要

The global neurology drugs market is estimated to be valued at USD 74 Bn in 2026 and is expected to reach USD 104 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.98% from 2026 to 2033. The global neurology drugs market is an important segment of the pharmaceutical industry, and its scope is to address complex diseases affecting the central and peripheral nervous systems. Neurology drugs include treatments for various diseases, such as epilepsy, Alzheimer's, Parkinson's, multiple sclerosis, migraine, stroke, and many more. The growth of the neurology drugs market is mainly propelled by an increase in the prevalence of neurological disorders, rising aging population, and an increased understanding of neurobiological mechanisms. The increased prevalence of neurological diseases, particularly in developed and emerging countries, is a key driver of the growth of the neurology drugs market. On the other hand, there are increased R&D activities by companies to introduce new therapies such as drug delivery systems, personalization of medicine, and new therapies for different conditions. The market is highly regulated, with clinical validation due to a complex risk profile associated with therapies for neurological conditions. Major factors such as patent expiration, generics, changes in healthcare infrastructure, and changes in clinical guidelines are other key drivers for this market. Furthermore, gene therapy, immunotherapy, and precision medicine are changing the current therapy landscape, thus providing new opportunities for the management of this condition. Market Dynamics The global neurology drugs market is fueled by various factors related to demography, technology, and healthcare. Growing cases of dementia, Parkinson’s disease, and epilepsy among the aging population contribute to the growth of the neurology drugs market. Improvements in drug discovery techniques, including the application of artificial intelligence in drug discovery, the identification of biomarkers, and the application of precision medicine, further propels the growth. Additionally, increasing healthcare expenditure, improvements in diagnostic techniques, and the expansion of the healthcare infrastructure in emerging markets also contribute to the growth of the neurology drugs market. However, there are certain challenges in this market, which include high R&D costs and regulatory approvals, which act as a restraint in this market for new entrants. The expiration of patents on blockbuster drugs creates a competitive environment in the generics segment, which affects the revenue received by these companies. Challenges in clinical trials, ethical issues, and high failure rates in late-stage drug development are other issues in this market. In addition, there are safety issues and the occurrence of adverse effects, which necessitate surveillance in this market. Despite the challenges, there are many opportunities in this market, especially in the new markets of developing nations, which are growing in terms of healthcare infrastructure and medical tourism. Orphan drugs for neurological disorders, digital therapeutics, combination therapies, and drug delivery systems are opportunities in this market for future growth. Key Features of the Study • This report provides in-depth analysis of the global neurology drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global neurology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co., Teva Pharmaceutical Industries, Eisai, H. Lundbeck, UCB, Otsuka Pharmaceutical, and Jazz Pharmaceuticals • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global neurology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurology drugs market Market Segmentation • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Alzheimer’s Disease o Parkinson’s Disease o Epilepsy o Multiple Sclerosis o Migraine o Huntington’s Disease o Others • Drug Class Insights (Revenue, USD Bn, 2021 - 2033) o Antiepileptics o Antipsychotics o Dopamine Agonists o Cholinesterase Inhibitors o NMDA Receptor Antagonists o Analgesics (Migraine-specific) o Others • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033) o Oral o Injectable o Transdermal • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o F. Hoffmann-La Roche o Johnson & Johnson o AbbVie o Merck & Co. o Teva Pharmaceutical Industries o Eisai o Lundbeck o UCB o Otsuka Pharmaceutical o Jazz Pharmaceuticals

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Neurology Drugs Market, By Disease Type  Global Neurology Drugs Market, By Drug Class  Global Neurology Drugs Market, By Route of Administration  Global Neurology Drugs Market, By Distribution Channel  Global Neurology Drugs Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Neurology Drugs Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Alzheimer’s Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Parkinson’s Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Epilepsy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Multiple Sclerosis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Migraine  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Huntington’s Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Neurology Drugs Market, By Drug Class, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Antiepileptics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Antipsychotics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Dopamine Agonists  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cholinesterase Inhibitors  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o NMDA Receptor Antagonists  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Analgesics (Migraine-specific)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Neurology Drugs Market, By Route of Administration, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Injectable  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Transdermal  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Neurology Drugs Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Neurology Drugs Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o F. Hoffmann-La Roche  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AbbVie  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceutical Industries  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eisai  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Lundbeck  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o UCB  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Otsuka Pharmaceutical  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Jazz Pharmaceuticals  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'Neurology Drugs Market' - Global forecast to 2033

提及公司

F. Hoffmann-La RocheJohnson & JohnsonAbbVieMerck & Co.Teva Pharmaceutical IndustriesEisaiLundbeckUCBOtsuka PharmaceuticalJazz Pharmaceuticals

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們